Drug intelligence / Profile preview

VACh

Development stage: Unknown
Modality: Small Molecules

Overview

VACh is a combination drug comprising Venetoclax, Azacitidine, and Chidamide. It is being investigated for the treatment of newly diagnosed adult acute myeloid leukemia (AML) patients who are ineligible for intensive therapy or decline it. Venetoclax is a BCL2 inhibitor, Azacitidine is a hypomethylating agent, and Chidamide is a histone deacetylase inhibitor that can downregulate MCL1 expression in Venetoclax-resistant AML cells. The combination aims to achieve synergistic anti-leukemia effects by eradicating leukemia stem cells and preventing drug resistance. [cite: NCT06532552]

Other names: VACh regimenvenetoclax + azacitidine + tucidinostat

Targets

DNMT3B (DNA (cytosine-5)-methyltransferase 3B)Bcl-w (B-cell lymphoma 2-like 2)DNMT3A (DNA methyltransferase 3 alpha)BCL2L1 (B-cell lymphoma-extra large protein)HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)DNMT1 (DNA (cytosine-5)-methyltransferase 1)

Beyond the preview

Go deeper on VACh.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VACh.

Explore the full profile